This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Buy Abiomed (ABMD) Stock Right Now
by Zacks Equity Research
Abiomed's (ABMD) solid Impella product line and the inclusion in the S&P 500 connect make it a lucrative pick.
Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up
by Zacks Equity Research
Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.
Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe
by Zacks Equity Research
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.
NuVasive's (NUVA) Global Prospects Solid, Competition Rife
by Zacks Equity Research
NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.
Here's Why You Should Invest in Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker's (SYK) focus on inorganic expansion and stellar Mako performance make the stock an attractive buy.
Boston Scientific Grows on New Products Amid Recall Issues
by Zacks Equity Research
Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.
Bruker Unveils New Mass-Spectrometry Products, Boosts CALID
by Zacks Equity Research
Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.
4 Medical Device Stocks with Solid Potential to Buy Now
by Zacks Equity Research
The Medical Device tax suspension spells good times for MedTech bigwigs.
Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.
by Zacks Equity Research
Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.
Illumina (ILMN) Grows on Innovation & Strategic Partnerships
by Zacks Equity Research
Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.
Here's Why You Should Invest in PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) gains from stellar Q1 performance; a raised guidance holds promise.
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is Intuitive Surgical, Inc. (ISRG) Outperforming Other Medical Stocks This Year?
ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business
by Zacks Equity Research
Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.
US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch
by Nabaparna Bhattacharya
Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market
Intuitive Surgical Commences Direct Operations in India
by Zacks Equity Research
Intuitive Surgical (ISRG) looks to install a broader base of its flagship da Vinci surgical system through distributor Vattikuti in India.
Here's Why You Should Add ResMed (RMD) to Your Portfolio Now
by Zacks Equity Research
With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.
Here's Why STERIS (STE) Stock is a Must Buy at the Moment
by Zacks Equity Research
STERIS (STE) gains ground on strategic buyouts and divestments.
Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.
IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG
by Zacks Equity Research
Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.
Abbott Presents Positive Data for AMPLATZER Amulet Device
by Zacks Equity Research
Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.
Merit Medical (MMSI) Up 18.9% in a Month on Solid Q1 Earnings
by Zacks Equity Research
Merit Medical (MMSI) reports strong Q1 earnings and sees solid growth across segments and geographies.
Quality Systems (QSII) Q4 Earnings Beat, Bookings Rise Y/Y
by Zacks Equity Research
Quality Systems (QSII) exits fourth quarter on a solid note with a surge in bookings; issues a solid guidance for fiscal 2019.
Abbott Presents Positive Study Results for Tendyne Device
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.
Veeva Systems (VEEV) Beats Q1 Earnings Estimates, Raises View
by Zacks Equity Research
Solid performance in Subscription revenues is a key catalyst for Veeva Systems (VEEV) in Q1.